Cytokinetics suspends development of ALS candidate on Phase III miss

Cytokinetics Inc. (NASDAQ:CYTK) said it will suspend development of tirasemtiv after the candidate missed the primary and secondary endpoints in the Phase III VITALITY-ALS trial to treat amyotrophic lateral sclerosis (ALS). On the double-blind, international trial's primary endpoint, tirasemtiv failed to significantly improve slow vital

Read the full 455 word article

User Sign In